Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial

Regeneron’s experimental obesity drug, combined with Novo Nordisk’s semaglutide, reduced muscle-mass loss by 50% versus semaglutide alone in a patient study. The data, presented at a medical meeting, could differentiate Regeneron’s obesity-treatment approach by addressing a key concern around GLP-1-related lean-mass loss.